Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The overlooked trauma: psychological violence and its impact on PTSD symptoms.

European journal of psychotraumatology·2026
Same author

Blunted Brain Reactivity To Mutilation Pictures in Patients with Posttraumatic Stress Disorder and Exposure To Childhood Sexual Abuse: An fMRI Study.

Journal of child & adolescent trauma·2026
Same author

Vulnerability and protective factors for PTSD in the academic community during the pandemic.

Psicologia, reflexao e critica : revista semestral do Departamento de Psicologia da UFRGS·2026
Same author

Prevalence of Victimization Among Adults with Severe Mental Illness Worldwide: A Systematic Review and Meta-Analysis.

Trauma, violence & abuse·2025
Same author

Is virtual reality always better than 2D videos? A head-to-head randomized controlled trial for fear of flying with long-term follow-up.

Psychiatry research·2025
Same author

Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2025

Related Experiment Video

Updated: Jun 23, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Aerosol devices and asthma therapy.

William Berger1

  • 1Allergy & Asthma Associates of Southern CA, 27800 Medical Center Road, Suite #244, Mission Viejo, CA 92691-6410, USA. weberger@uci.edu

Current Drug Delivery
|May 8, 2009
PubMed
Summary

Choosing the right asthma inhaler is key for effective medication delivery. This review compares pressurized metered-dose inhalers, dry powder inhalers, and nebulizers, considering patient needs and device characteristics for optimal lung deposition.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Aerosolized asthma medications offer targeted lung delivery, minimizing systemic side effects compared to oral treatments.
  • The Montreal Protocol spurred innovation in inhaled asthma medication delivery devices, replacing chlorofluorocarbon (CFC) propellants.
  • Hydrofluoroalkane (HFA) propellants now feature in pressurized metered-dose inhalers (pMDIs), alongside new dry powder inhalers (DPIs) and nebulizers.

Purpose of the Study:

  • To review key characteristics of various aerosol delivery devices for asthma medications.
  • To explain differences in lung deposition markers across device types.
  • To discuss factors influencing the selection of appropriate inhaler devices for individual patient needs.

Main Methods:

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Related Experiment Videos

Last Updated: Jun 23, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

  • Comparative review of aerosol delivery technologies for asthma treatment.
  • Analysis of drug delivery variations based on device type, formulation, and patient factors.
  • Evaluation of lung deposition, advantages, and disadvantages of different inhaler systems.

    • Main Results:

    • Drug delivery efficacy varies significantly between HFA pMDIs, CFC pMDIs, DPIs, and nebulizers.
    • Inhaler design and drug formulation differences exist even within the same device category (e.g., DPIs, pMDIs).
    • Patient-specific factors, including usability, medication availability, and preference, are critical for device selection.

    Conclusions:

    • Optimal asthma management requires careful consideration of inhaler device characteristics and patient-specific needs.
    • Understanding device-specific drug delivery and lung deposition is crucial for effective treatment.
    • Personalized selection of inhaler devices ensures better adherence and therapeutic outcomes in asthma patients.